Literature DB >> 27261186

The impact of long-term secukinumab treatment on Epstein-Barr virus and cytomegalovirus loads in patients with psoriasis.

Hsien-Yi Chiu1,2,3, Chih-Chieh Chan3, Tsen-Fang Tsai4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27261186     DOI： 10.1111/ijd.13346

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  4 in total

1.  CMV Infection: A Clinical Challenge in Biological Therapy? The Case of Asymptomatic Patients with Persistent Positive Immunoglobulin M Anti-CMV Treated with Secukinumab.

Authors:  Alessio Gambardella; Gaetano Licata; Giulia Calabrese; Alina De Rosa; Francesca Pagliuca; Roberto Alfano; Giuseppe Argenziano
Journal:  Psoriasis (Auckl)       Date:  2020-11-27

Review 2.  HLA-Cw1 and Psoriasis.

Authors:  Yi-Wei Huang; Tsen-Fang Tsai
Journal:  Am J Clin Dermatol       Date:  2021-01-18       Impact factor: 7.403

3.  Perception of the threat, mental health burden, and healthcare-seeking behavior change among psoriasis patients during the COVID-19 pandemic.

Authors:  Hsien-Yi Chiu; Nien-Feng Chang Liao; Yu Lin; Yu-Huei Huang
Journal:  PLoS One       Date:  2021-12-09       Impact factor: 3.240

4.  The seroconversion rate of QuantiFERON-TB Gold In-Tube test in psoriatic patients receiving secukinumab and ixekizumab, the anti-interleukin-17A monoclonal antibodies.

Authors:  Chen-Yu Wu; Hsien-Yi Chiu; Tsen-Fang Tsai
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.